Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis

Publication Date

2020

Journal Title

Curr Opin Rheumatol

Abstract

PURPOSE OF REVIEW: It is an understatement to say that drug approvals in systemic lupus erythematosus (SLE), lupus nephritis, and Sjogren's syndrome have lagged far behind those in other autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis. Reasons for this are multiple and include the molecular and clinical heterogeneity of these conditions; confounding by background medications, especially corticosteroids; and clinical trial endpoints. However, the tides are changing, and there have been several bright spots in our attempts to bring more efficacious drugs to our patients. RECENT FINDINGS: Several positive phase II and phase III trials in SLE and lupus nephritis with drugs such as anifrolumab, voclosporin, belimumab, and obinutuzumab will no doubt eventually generate regulatory approvals for most, if not all, of these drugs. Although early in development, the promising results in Sjogren's syndrome with iscalimab and ianalumab should make the Sjogren's syndrome community quite hopeful of future drug approvals. SUMMARY: In this review, we highlight recent study results in Sjogren's syndrome, SLE, and lupus nephritis, emphasizing investigational therapies in late stage development, but we also provide a glimpse into drugs of the future.

Volume Number

32

Issue Number

6

Pages

609 - 616

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Rheumatology

PMID

33002950

DOI

10.1097/BOR.0000000000000754

For the public and Northwell Health campuses

Share

COinS